Plecanatide vs Ipamorelin
Head-to-head comparison of Plecanatide (Plecanatide) and Ipamorelin (Growth Hormone Secretagogue) — benefits, dosing, side effects, research data, and where to buy.
Research Score
| Property | Plecanatide | Ipamorelin |
|---|---|---|
| Category | Gastrointestinal | Performance |
| Full Name | Plecanatide | Growth Hormone Secretagogue |
| Molecular Weight | Approx. 1620 Da | 711.85 Da |
| Half-Life | Local intestinal action; systemic half-life not clinically meaningful | ~2 hours |
| Amino Acids | 16 | 5 |
| Typical Dose | 3 mg once daily | 200-300 mcg |
| Route | Oral | SC |
| Purity | ≥98% | — |
| Studies Count | 350 | 156 |
| Research Status | Clinical | Clinical Trials |
Plecanatide Benefits
- ✓improves-stool-frequency
- ✓supports-fluid-secretion
- ✓may-reduce-constipation
- ✓local-gut-action
Ipamorelin Benefits
- ✓Stimulates natural GH release
- ✓Minimal cortisol/prolactin increase
- ✓Improved body composition
- ✓Enhanced recovery and sleep quality
- ✓Anti-aging effects
Plecanatide Dosing
3 mg PO daily|take with or without food|avoid when dehydrated
Ipamorelin Dosing
Standard: 200-300 mcg SC 2-3 times daily|Pre-bed: 200 mcg SC 30 min before sleep|Combined: 100-200 mcg with CJC-1295 2-3x daily
Plecanatide Side Effects
- ⚠diarrhea
- ⚠abdominal-discomfort
- ⚠nausea
Ipamorelin Side Effects
- ⚠Common (Mild): Temporary tingling, water retention, increased appetite
- ⚠Rare: Headache, lightheadedness
- ⚠Very Well Tolerated overall
Research Overview
Plecanatide
Clinical trials show plecanatide improves constipation outcomes with a generally favorable tolerability profile. Like linaclotide, it acts locally in the intestinal lumen via GC-C signaling rather than systemic hormone effects.
Ipamorelin
Ipamorelin has moderate clinical evidence. Phase II trials demonstrate selective GH release. Generally regarded as one of the safest GH secretagogues with minimal side effect profile.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.